🟢 Nuvation Bio Inc. is trading 5.3% up today after advancing IBTROZI and safusidenib trials and regulatory filings

Nuvation Bio Inc. is trading 5.3% up at $5.86 after announcing the advancement of clinical trials and regulatory filings for its lead candidates, IBTROZI and safusidenib.

• The stock is significantly outperforming the broader market, with the NASDAQ Composite down 0.95% during the session.
• The price action is being driven by company-specific clinical-development milestones rather than broader macroeconomic trends.